Formations et évènements

ESMO 2023

L’IFCT sera présent à l’ESMO 2023 avec 2 communications orales & 2 posters :

Radiotherapy boost to 74 Gy based on FDG-PET at 42 Gy of radiochemotherapy (RCT) in patients with inoperable stage III non-small cell lung cancer (RTEP7-IFCT-1402): a prospective multicentre, open-label, randomised, controlled trial.
Communication orale - 20.10.2023
Gérard Zalcman
Abstract

Impact of a minimal versus CT-scan-based follow-up on patient-reported outcomes for completely resected non-small cell lung cancer (NSCLC) in phase III IFCT-0302 trial
Communication orale - 21.10.2023
Guillaume Eberst
Abstract

Osimertinib in patients with EGFR-mutated NSCLC and leptomeningeal or brain metastases: Results of the IFCT-1804 ORBITAL trial
Poster - 23.10.2023
David Planchard
Abstract
Poster

Real-world effectiveness and safety of sotorasib in patients with KRAS G12C mutated metastatic non-small cell lung cancer (NSCLC): Results of the IFCT-2102 Lung KG12Ci study
Poster - 23.10.2023
Marie Wislez
Abstract
Poster

Retrouvez les abstracts IFCT sur : https://cslide.ctimeetingtech.com/esmo2023/attendee/confcal/presentation/list?q=ifct